- Home
- BLKB vs GH Comparison
BLKB vs GH Comparison
Compare BLKB & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLKB
- GH
- Stock Information
- Founded
- BLKB 1981
- GH 2011
- Country
- BLKB United States
- GH United States
- Employees
- BLKB N/A
- GH N/A
- Industry
- BLKB Computer Software: Prepackaged Software
- GH Medical Specialities
- Sector
- BLKB Technology
- GH Health Care
- Exchange
- BLKB Nasdaq
- GH Nasdaq
- Market Cap
- BLKB 4.0B
- GH 3.0B
- IPO Year
- BLKB 2004
- GH 2018
- Fundamental
- Price
- BLKB $83.45
- GH $25.65
- Analyst Decision
- BLKB Buy
- GH Strong Buy
- Analyst Count
- BLKB 1
- GH 17
- Target Price
- BLKB $92.00
- GH $39.31
- AVG Volume (30 Days)
- BLKB 157.3K
- GH 2.3M
- Earning Date
- BLKB 10-29-2024
- GH 11-04-2024
- Dividend Yield
- BLKB N/A
- GH N/A
- EPS Growth
- BLKB N/A
- GH N/A
- EPS
- BLKB 0.77
- GH N/A
- Revenue
- BLKB $1,139,173,000.00
- GH $643,810,000.00
- Revenue This Year
- BLKB $8.46
- GH $27.01
- Revenue Next Year
- BLKB $7.67
- GH $18.30
- P/E Ratio
- BLKB $105.50
- GH N/A
- Revenue Growth
- BLKB 6.58
- GH 26.20
- 52 Week Low
- BLKB $64.32
- GH $15.81
- 52 Week High
- BLKB $88.56
- GH $37.04
- Technical
- Relative Strength Index (RSI)
- BLKB 61.81
- GH 47.12
- Support Level
- BLKB $80.41
- GH $24.55
- Resistance Level
- BLKB $82.11
- GH $25.87
- Average True Range (ATR)
- BLKB 1.31
- GH 1.13
- MACD
- BLKB -0.09
- GH 0.18
- Stochastic Oscillator
- BLKB 50.00
- GH 69.88
About BLKB Blackbaud Inc.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.